Ulisse Biomed Future Growth

Future criteria checks 2/6

Ulisse Biomed is forecast to grow earnings and revenue by 74.6% and 92.3% per annum respectively.

Key information

74.6%

Earnings growth rate

n/a

EPS growth rate

Biotechs earnings growth34.9%
Revenue growth rate92.3%
Future return on equityn/a
Analyst coverage

Low

Last updated24 May 2024

Recent future growth updates

Recent updates

Earnings and Revenue Growth Forecasts

BST:8XX - Analysts future estimates and past financials data (EUR Millions)
DateRevenueEarningsFree Cash FlowCash from OpAvg. No. Analysts
12/31/20253-20N/A1
12/31/20242-3-1N/A1
6/30/20240-7N/AN/AN/A
3/31/20240-6N/AN/AN/A
12/31/20230-5N/AN/AN/A
9/30/20230-3N/AN/AN/A
6/30/20230-2-2-1N/A
3/31/20230-1-1-1N/A
12/31/20220-1-1-1N/A
9/30/20220-1N/AN/AN/A
6/30/20220-1-2-1N/A
3/31/20220-1-2-1N/A
12/31/20210-1-10N/A
9/30/202100N/AN/AN/A
6/30/20211001N/A
3/31/20211000N/A
12/31/202010-1-1N/A
12/31/20190-100N/A
12/31/20180-2N/AN/AN/A

Analyst Future Growth Forecasts

Earnings vs Savings Rate: 8XX is forecast to remain unprofitable over the next 3 years.

Earnings vs Market: 8XX is forecast to remain unprofitable over the next 3 years.

High Growth Earnings: 8XX is forecast to remain unprofitable over the next 3 years.

Revenue vs Market: 8XX's revenue (92.3% per year) is forecast to grow faster than the German market (5.5% per year).

High Growth Revenue: 8XX's revenue (92.3% per year) is forecast to grow faster than 20% per year.


Earnings per Share Growth Forecasts


Future Return on Equity

Future ROE: Insufficient data to determine if 8XX's Return on Equity is forecast to be high in 3 years time


Discover growth companies